EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment

Subtypes of EGFR and HER2 mutant metastatic NSCLC influence response to immune checkpoint inhibitors

(2021) Sally CM. Lau et al.   Clinical Lung Cancer

36MO Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer

(2021) A. Sacher et al.   ANNALS OF ONCOLOGY

Response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma with EGFR exon 20 insertions

(2021) Noura J. Choudhury et al.   CLINICAL CANCER RESEARCH

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial

(2021) Gregory J. Riely et al.   Cancer Discovery

Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer

(2021) Francois Gonzalvez et al.   Cancer Discovery

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer

(2021) Said A. Khelwatty et al.   Cancers

Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations

(2021) Shuo Yang et al.   Translational Lung Cancer Research

Immunotherapy in non-small cell lung cancer harbouring driver mutations

(2021) Alfredo Addeo et al.   CANCER TREATMENT REVIEWS

Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program

(2021) Arsela Prelaj et al.   EUROPEAN JOURNAL OF CANCER

OA04.03 Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations

(2021) C. Zhou et al.   Journal of Thoracic Oncology

Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib

(2021) Han Han et al.   CANCER RESEARCH

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

(2021) Keunchil Park et al.   JOURNAL OF CLINICAL ONCOLOGY

Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.

(2021) James Chih-Hsin Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies.

(2021) Alison M. Schram et al.   JOURNAL OF CLINICAL ONCOLOGY

Interim results of a phase II single arm trial combining afatinib with cetuximab in patients with EGFRex20ins positive NSCLC.

(2021) Bianca van Veggel et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20).

(2021) Zofia Piotrowska et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.

(2021) Julien Mazieres et al.   JOURNAL OF CLINICAL ONCOLOGY

Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.

(2021) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC.

(2021) Catherine A. Shu et al.   JOURNAL OF CLINICAL ONCOLOGY

A narrative review of advances in treatment and survival prognosis of HER2-positive malignant lung cancers

(2021) Ranpu Wu et al.   Journal of Thoracic Disease

Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions

(2020) Russell W. Madison et al.   BJU INTERNATIONAL

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

(2020) Shanu Modi et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced Non Small Cell Lung Cancer with BRAF, HER2 or MET mutation or RET-translocation. GFPC 01-2018.

(2020) Florian Guisier et al.   Journal of Thoracic Oncology

Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma

(2020) Shen Zhao et al.   Journal of Thoracic Oncology

TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC

(2020) Julia Roeper et al.   Oncotarget

Molecular profiling for precision cancer therapies

(2020) Eoghan R. Malone et al.   Genome Medicine

Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan‐cancer analysis

(2020) Haijing Liu et al.   Cancer Communications

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases

(2020) Philip C. Mack et al.   CANCER

The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal

(2020) Valerio Gristina et al.   CANCER TREATMENT REVIEWS

Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC

(2020) Iosune Baraibar et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions.

(2020) Zofia Piotrowska et al.   JOURNAL OF CLINICAL ONCOLOGY

Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients.

(2020) Xiuning Le et al.   JOURNAL OF CLINICAL ONCOLOGY

Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).

(2020) Keunchil Park et al.   JOURNAL OF CLINICAL ONCOLOGY

Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions.

(2020) Leora Horn et al.   JOURNAL OF CLINICAL ONCOLOGY

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.

(2020) Binghe Xu et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study

(2020) Guangjian Yang et al.   LUNG CANCER

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

(2020) Kohei Shitara et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

(2020) Junji Tsurutani et al.   Cancer Discovery

Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis

(2020) Qitong Chen et al.   Frontiers in Oncology

New therapeutic approaches to overcoming resistant EGFR exon 20 alterations

(2020) Alex M. Li et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study

(2020) Caicun Zhou et al.   JOURNAL OF CLINICAL ONCOLOGY

HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib

(2020) Xinyong Zhang et al.   Frontiers in Oncology

1388P Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: Initial results from a single site expanded access program

(2020) A. Prelaj et al.   ANNALS OF ONCOLOGY

11P Preclinical evaluation of DS-2087b, a novel and selective inhibitor of EGFR/HER2 exon 20 insertions

(2020) Y. Nagamoto et al.   ANNALS OF ONCOLOGY

LBA60 ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations

(2020) M.A. Socinski et al.   ANNALS OF ONCOLOGY

LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions

(2020) S.V. Liu et al.   ANNALS OF ONCOLOGY

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

(2020) Benjamin C. Creelan et al.   BRITISH JOURNAL OF CANCER

Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non–Small-Cell Lung Cancer: Final Results From SWOG S1403

(2020) Sarah B. Goldberg et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib

(2020) Niamh Coleman et al.   Journal of Thoracic Oncology

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

(2020) Adriana Estrada-Bernal et al.   CLINICAL CANCER RESEARCH

Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions

(2020) Kaiyan Chen et al.   Thoracic Cancer

A pan-cancer analysis of HER2 index revealed transcriptional pattern for precise selection of HER2-targeted therapy

(2020) Ziteng Li et al.   EBioMedicine

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario

(2019) Alessandro Russo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC

(2019) Alex Friedlaender et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

A Patient with EGFR Exon 20 Insertion–Mutant Non–Small Cell Lung Cancer Responded to Osimertinib plus Cetuximab Combination Therapy

(2019) Wenfeng Fang et al.   Journal of Thoracic Oncology

HER2-targeted therapies — a role beyond breast cancer

(2019) Do-Youn Oh et al.   Nature Reviews Clinical Oncology

1529PPhase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)

(2019) T M Kim et al.   ANNALS OF ONCOLOGY

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

(2019) Jacqulyne P. Robichaux et al.   CANCER CELL

Durable Response of Low-Dose Afatinib plus Cetuximab in an Adenocarcinoma Patient with a Novel EGFR Exon 20 Insertion Mutation

(2019) Wenfeng Fang et al.   Journal of Thoracic Oncology

P2.01-51 Next-Generation Sequencing for Effective Detection of Various EGFR Exon 20 Insertions (E20ins) in Non-Small Cell Lung Cancer (NSCLC)

(2019) I. Hwang et al.   Journal of Thoracic Oncology

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

(2019) Suresh S. Ramalingam et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

(2019) Lillian M. Smyth et al.   Cancer Discovery

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

(2018) Neal I. Lindeman et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer

(2018) Namita Sharma et al.   CANCER TREATMENT REVIEWS

Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario

(2018) Alfredo Addeo et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial

(2018) Bob T. Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion–Positive Advanced NSCLC

(2018) Bianca van Veggel et al.   Journal of Thoracic Oncology

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer

(2018) Jonathan W. Riess et al.   Journal of Thoracic Oncology

A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model

(2018) Tomomi Nakayama Iwata et al.   MOLECULAR CANCER THERAPEUTICS

TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations

(2018) Shinichi Hasako et al.   MOLECULAR CANCER THERAPEUTICS

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

(2018) Jacqulyne P. Robichaux et al.   NATURE MEDICINE

EGFR exon 20 insertion mutation in advanced thymic squamous cell carcinoma: Response to apatinib and clinical outcomes

(2018) Su Yudong et al.   Thoracic Cancer

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers

(2018) Pedram Razavi et al.   CANCER CELL

Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer.

(2018) Marcelo Vailati Negrao et al.   JOURNAL OF CLINICAL ONCOLOGY

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

(2018) David M. Hyman et al.   NATURE

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib

(2018) Y Wang et al.   ANNALS OF ONCOLOGY

Metastatic Breast Cancer Patient With Activating HER2 Exon 20 Insertion Mutation With Response to Poziotinib: Case Report of Compassionate Drug Use

(2018) Apurva Pandey et al.   Clinical Breast Cancer

Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial

(2018) Dhivya R. Sudhan et al.   CLINICAL CANCER RESEARCH

EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP)

(2018) Andrés F. Cardona et al.   LUNG CANCER

Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations

(2018) Hanako Hasegawa et al.   LUNG CANCER

Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage

(2018) Sandra Rayego-Mateos et al.   MEDIATORS OF INFLAMMATION

Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

(2017) Fei Ma et al.   JOURNAL OF CLINICAL ONCOLOGY

OA 12.02 Final Results of a Phase 2 Study of the hsp90 Inhibitor Luminespib (AUY922) in NSCLC Patients Harboring EGFR Exon 20 Insertions

(2017) Z. Piotrowska et al.   Journal of Thoracic Oncology

Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis

(2017) Chee Khoon Lee et al.   Journal of Thoracic Oncology

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

(2017) Ahmet Zehir et al.   NATURE MEDICINE

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

(2017) Ken Uchibori et al.   Nature Communications

AACR Project GENIE: Powering Precision Medicine through an International Consortium

(2017)   Cancer Discovery

Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways

(2017) et al.   Cancers

Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The “Rotation Model”

(2017) Endang Purba et al.   Cells

LBA39_PRNERATINIB (N) WITH OR WITHOUT TEMSIROLIMUS (TEM) IN PATIENTS (PTS) WITH NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING HER2 SOMATIC MUTATIONS: AN INTERNATIONAL RANDOMIZED PHASE II STUDY

(2017) B. Besse et al.   ANNALS OF ONCOLOGY

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment

(2016) J L Kuiper et al.   BRITISH JOURNAL OF CANCER

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors

(2016) Sheri L. Moores et al.   CANCER RESEARCH

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

(2016) Yoshihisa Kobayashi et al.   CANCER SCIENCE

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

(2016) Y. Ogitani et al.   CLINICAL CANCER RESEARCH

Pulse Afatinib for ERBB2 Exon 20 Insertion–Mutated Lung Adenocarcinomas

(2016) Daniel B. Costa et al.   Journal of Thoracic Oncology

Lung cancer patients withHER2mutations treated with chemotherapy andHER2-targeted drugs: results from the European EUHER2 cohort

(2015) J. Mazières et al.   ANNALS OF ONCOLOGY

Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses

(2015) Gideon M. Blumenthal et al.   JOURNAL OF CLINICAL ONCOLOGY

Maximizing the Therapeutic Potential of HSP90 Inhibitors

(2015) L. M. Butler et al.   MOLECULAR CANCER RESEARCH

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

(2015) Sandra M. Swain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer

(2015) Igor F. Tsigelny et al.   Oncotarget

Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma

(2014) Hye Ryun Kim et al.   LUNG CANCER

HER2 status in lung adenocarcinoma: A comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations

(2014) Akihiko Yoshizawa et al.   LUNG CANCER

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network

(2013) M. Beau-Faller et al.   ANNALS OF ONCOLOGY

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Comparison of Targeted Next-Generation Sequencing (NGS) and Real-Time PCR in the Detection ofEGFR,KRAS,andBRAFMutations on Formalin-Fixed, Paraffin-Embedded Tumor Material of Non-Small Cell Lung Carcinoma-Superiority of NGS

(2013) Katja Tuononen et al.   GENES CHROMOSOMES & CANCER

Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

(2013) Julien Mazières et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors

(2013) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

(2013) Neal I. Lindeman et al.   Journal of Thoracic Oncology

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

(2013) Geoffrey R. Oxnard et al.   Journal of Thoracic Oncology

Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non-Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations

(2013) J. J. Wheler et al.   MOLECULAR CANCER THERAPEUTICS

EGFR Exon 20 Insertion A763-Y764insFQEA and Response to Erlotinib—Letter

(2013) Pei Jye Voon et al.   MOLECULAR CANCER THERAPEUTICS

EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

(2013) M. E. Arcila et al.   MOLECULAR CANCER THERAPEUTICS

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

(2013) H. Yasuda et al.   Science Translational Medicine

Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas

(2012) M. E. Arcila et al.   CLINICAL CANCER RESEARCH

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu

(2012) J. De Grève et al.   LUNG CANCER

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Comparison of EGFR Mutation Testing Methods in Lung Carcinoma: Direct Sequencing, Real-time PCR and Immunohistochemistry

(2012) Bárbara Angulo et al.   PLoS One

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

(2012) R. Katayama et al.   Science Translational Medicine

Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

(2012) Ron Bose et al.   Cancer Discovery

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab

(2011) Toni M. Brand et al.   CANCER BIOLOGY & THERAPY

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

(2011) Hiroyuki Yasuda et al.   LANCET ONCOLOGY

An integrated semiconductor device enabling non-optical genome sequencing

(2011) Jonathan M. Rothberg et al.   NATURE

Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer

(2010) Takeshi Yoshida et al.   BIOCHEMICAL PHARMACOLOGY

Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer

(2010) A. Kitamura et al.   CLINICAL CANCER RESEARCH

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer

(2009) Michael J. Eck et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy

(2009) S. A. Perera et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA